Alimentary Pharmacology and Therapeutics 1992: Vol 6 Index

9 Pages·1992·1.3 MB·English

Aliment. Pharmacol. Ther. (1992) 6, 763-771
Index
8 C-urea breath test, 97 antibiotics, 291
24-h intragastric pH, 381 antioxidant therapy, 231
24-h profile of plasma pepsinogen I, 389 antisecretory, 189
24-h profile of plasma pepsinogen II, 389 arachidonic acid, 165
24-h profile of plasma gastrin, 389 Ardill, J. E. S. see Fullarton, G. M.
5-aminosalicylic acid, 261, 671 Arnold, J. see Swift, G. L.
5-ASA, 51 artificial duodenum, 447
5-ASA compounds, 647 artificial stomach, 447
5-HT,-like agonist, 685 aspirin, 707
at-adrenoreceptors, 415 Astier, A. see Petitjean, O.
a-adrenoreceptor agonist, 125, 253 atenolol, 701
at-adrenoreceptor antagonist, 125, 253 Ayesu, K. see Moss, S. F.
Aabakken, L., Review article: non-steroidal, anti- Aziz, K. see Dakkak, M.
inflammatory drugs—the extending scope of gas-
trointestinal side effects, 143 f-adrenoreceptor agonist, 123, 253
abdominal symptoms, 437 f-adrenoreceptor antagonist, 123, 253
absorption, 701 f-carotene, 231
acetorphan, 305 Back, D. J. see Grimmer, S. F. M.
acetyl-5-aminosalicylic acid, 671 balsalazide, 479, 647
achalasia, 507 Barish, C. see Roufail, W.
acid, 707 Baron, J. H. see Giaffer, M. H.
acid inhibition, 381 Barrison, I. G. see Giaffer, M. H.
acid secretion, 291, 359, 407 Baumer, P. see Bergmann, J. F.
acidity, 373 Beattie, S. see Patchett, S.
adverse reactions, 609 Bell, G. D. see Weil, J.
Africa, 119 Bell, G. D., Powell, K., Burridge, S. M., Harrison, G.,
Alberola, B. see Cortot, A. Weil, J., Gant, P. W., Jones, P. H., Trowell, J. E.,
alcohol low-dose 0.15 g/kg, 269 Does a previous course of tripotassium dicitrato
alcohol withdrawal, 541 bismuthate affect the subsequent chances of suc-
alcoholic cirrhosis, 541 cessful Helicobacter pylori eradication?, 327
alcoholic hepatitis, 541 Bell, G. D., Powell, K., Burridge, S. M., Pallecaros, A.,
alcoholic liver disease, 541 Jones, P. H., Gant, P. W., Harrison, G., Trowell,
alginate, 579 J. E., Experience with ‘triple’ anti- Helicobacter pylori
allergic, 51 eradication therapy: side effects and the import-
aluminium salts, 447 ance of testing the pre-treatment bacterial isolate
ammonia, 659 for metronidazole resistance, 427
ammonium, 659 Bell, G. D., Powell, K., Burridge, S. M., Spencer, G.,
Annibale, B. see Delle Fave, G. Bolton, G., Purser, K., Brooks, S., Prosser, S.,
antacid, 119, 181, 447, 579 Harrison, G., Gant, P. W., Jones, P. H., Trowell,
antacid in-vitro evaluation, 447 J. E., Short report: omeprazole plus antibiotic com-
763
764 INDEX
binations for the eradication of metronidazole- Burget, D. W. see Chiverton, S. G.
resistant Helicobacter pylori, 751 Burnham, W. R. see McIntyre, A. S.
Belsito, A. see Roufail, W. Burridge, S. M. see Bell, G. D.
Benati, G. see Corazza, G. R. Byers, C. A. see Morrison, G.
Bendtzen, K. see Langholz, E.
Bennett, A. see Swift, G. L. Calam, J. see Moss, S. F.
Bennett, J. R. see Dakkak, M. calcium, 399
Bergmann, J. F., Chaussade, S., Couturier, D., Baumer, calcium channel blockade, 165
P., Schwartz, J.C., Lecomte, J.M., Effects of Calza, G. see Corazza, G. R.
acetorphan, an antidiarrhoeal enkephalinase inhibi- carcinoid syndrome, 273
tor, on orocaecal and colonic transit times in Carnaby, S. see Hunt, J. B.
healthy volunteers, 305 Cassetta, M. R. see Delle Fave, G.
Beukers, R., De Rave, S., Van Den Berg, J. W. O., cefprozil, 503
Schalm, S. W., Oral pharmacokinetics of cyclosp- cephalosporin, 503
orin in patients with primary biliary cirrhosis and Chagas’ disease, 507
patients with skin diseases, 459 Chaussade, S. see Bergmann, J. F.
Bibbey, D. see Haines, D. J. Chiverton, S.G., Howden, C. W., Burget, D. W.,
Binder, V. see Langholz, E. Hunt, R. H., Omeprazole (20 mg) daily given in the
bioavailability, 351 morning or evening: a comparison of effects on
bismuth, 97, 119, 291 gastric acidity, and plasma gastrin and omeprazole
bismuth salicylate, 97 concentration, 103
bismuth subnitrate, 97 cholestasis, 209
Black, D. L. see Bluhm, R. E. cimetidine, 181, 223, 315, 693, 701
bleeding, 707 Clark, M. L. see Hunt, J. B.
Blendis, L.M., Review article: the treatment of Classen, M. see Madaus, S.
alcoholic liver disease, 541 clinical trial, 181, 503
blood loss, 67 Coates, M. E. see Melarange, R.
Blower, P. R. see Melarange, R. coeliac disease, 79
Bluhm, R. E., Rodgers, W. H., Black, D. L., Wilkinson, colalamin, 399
G.R., Branch, R.A., Cholestasis in transplant Cole, A. T., Brundell, S., Hudson, N., Hawthorne, A.
patients—what is the role of cyclosporin, 207 B., Mahida, Y. R., Hawkey, C. J., Ranitidine: dif-
Bolton, G. see Bell, G. D. ferential effects on gastric bleeding and mucosal
Boswell, D. J. see Greenfield, S. M. damage induced by aspirin, 707
Bottiglier, T. see Uden, S. colitis, ulcerative, 165
bowel preparation, 513 colon, 701
Boyd, E. J. S., Penston, J. G., Wormsley, K. G., Main- colonic motility, 589
tenance therapy in duodenal and gastric ulcer colonoscopy, 513
disease: survey of practice amongst British gas- combination treatment, 189
troenterologists, 727 contraceptive steroids, 79
Braganza, J. M., see Uden, S. conventional and germ-free rats, 67
Branch, R. A. see Bluhm, R. E. Corazza, G. R., Benati, G., Sorge, M., Strocchi, A.,
breath hydrogen, 61 Calza, G., Gasbarrini, G., f-Galactosidase from
Brenna, E., Waldum, H. L., Sandvik, A. K., Schulze Aspergillus niger in adult lactose malabsorption: a
Sognen, B., Kristensen, A., Effects on the rat double-blind crossover study, 61
oxyntic mucosa of the histamine,-antagonist lox- corticosteroids, 541
tidine and the H*, K*-ATPase inhibitor omepra- Cortot, A., Guillemot, F., Moreau, J., Soule, J. C.,
zole, 335 Veyrac, M., Alberola, B., Pappo, M., Influence of
Brooks, S. see Bell, G. D. the timing of administration of 300 mg ranitidine
Broom, C. see Hannan, A. on 24-hour gastric pH in patients with acute
Brown, P. see Green, J. R. B. duodenal ulcer, 487
Brundell, S. see Cole, A. T. Couturier, D. see Bergmann, J. F.
Brynskov, J. see Langholz, E. Crean, 549
Buchler, M. see Kemmer, T. P. Crohn's disease, 495
INDEX 765
cyclosporin, 495 Figueiredo, M. C. A., Oliveira, R. B., Iazigi, N., Mat-
cyclosporine, 209, 459 suda, N.M., Short report: comparison of the
cystic fibrosis, 549 effects of sublingual nifedipine and isosorbide
cytoprotection, 707 dinitrate on oesophageal emptying in patients with
Chagasic achalasia, 507
Dakkak, M., Aziz, K., Bennett, J. R., Short report: Flogerzi, B. see Schuerer-Maly, C.-C.
comparison of two orally administered bowel flumazenil, 745
preparations for colonoscopy—polyethylene fluorescent polarization immunoassay, 209
glycol and sodium picosulphate, 513 Ford, G. A., Oliver, P. S., Shepherd, N. A., Wilkinson,
Davies, G. S. R. see Giaffer, M. H. S. P., A Eudragit-coated prednisolone preparation
Day, G. M. see Sanders, S. W. for ulcerative colitis: pharmacokinetics and pre-
Day, J. P. see Uden, S. liminary therapeutic use, 31
De Rave, S. see Beukers, R. four and eight weeks of healing, 609
De-Noltabs, 97 Fowler, P. see Houghton, L. A.
delayed release indomethacin, 717 Franceschi, M. see Delle Fave, G.
Delle Fave, G., Annibale, B., Franceschi, M., Quatrini, Fraser, A. G. see Prewett, E. J.
M., Cassetta, M.R., Torsoli, A., Omeprazole Fraser, A. G., Hudson, M., Sawyerr, A. M., Rosalki,
versus famotidine in the short-term treatment of S.B., Pounder, R. E., Short report: the effect of
duodenal ulcer disease, 469 ranitidine on the post-prandial absorption of a low
Ditschuneit, H. see Kemmer, T. P. dose of alcohol, 267
Dodge, J. A. see Morrison, G. Fraser, A. G., Hudson, M., Sawyerr, A. M., Smith, M.,
domperidone, 223 Rosalki, S. B., Pounder, R. E., Ranitidine, cimetid-
double-blind study, 87 ine, famotidine have no effect on post-prandial
drug, 701 absorption of ethanol 0.8 g/kg taken after an
drug therapy, 181 evening meal, 693
duodenal pH, 447 Fraser, A. G., Prewett, E. J., Pounder, R. E., Samloff,
duodenal ulcer, 87, 113, 171, 253, 315, 469, 487, 659, I. M., Short report :t wenty-four-hour hyperpepsin-
727 ogenaemia in Helicobacter pylori-positive subjects is
abolished by eradication of the infection, 389
eicosanoids, 165 free radicals, 231
Ellis, A. see Grimmer, S. F. M. Friess, H. see Kemmer, T. P.
endoscopy sedation, 745 frusemide, 701
enterochromaffin-like cell, 335 Fullarton, G. M., Ardill, J. E. S., McColl, K. E. L., The
eradication of H. Pylori, 389 effect of H,-blockade on plasma gastrin concen-
erosive oesophagitis, 597 tration in patients with an achloryhydric stomach,
erythromycin, 589, 751 557
ethanol absorption, 693 fungal f-galactosidase added milk, 61
ethinyloestradiol metabolism, 79 fusidic acid, 495
Eudragit, 31
Evans, B. K. see Swift, G. L. Gant, P. W. see Bell, G. D.
Evans Jr, D. J. see Graham, D. Y. Gasbarrini, G. see Corazza, G. R.
exocrine pancrease, 41 gastric acid, 253, 487
gastric acid secretion, 197
Fairclough, P. D. see Hunt, J. B. gastric alcohol dehydrogenase, 693
famotidine, 87, 469, 693 gastric emptying, 223, 447
Farthing, M. J. G. see Hunt, J. B. gastric pH, 189, 487
Farup, P. G., Compliance with anti-ulcer medication gastric ulcer, 727
during short-term healing phase clinical trials, 179 gastrin, 103, 197, 373, 407, 469
Feldman, M., Goldschmiedt, M., Effect of potassium gastritis, antral, 253, 291
chloride on gastric acid secretion and gastrin gastro-oesophageal reflux, 273, 579
release in humans, 407 gastro-oesophageal reflux disease, 565, 597
Fenn, G. C., Correspondence, 654 gastrointestinal damage, 67
Festen, H. see Pounder, R. E. gastrointestinal motility, 125
766 INDEX
gastrointestinal secretion, 125 physiology and pharmacological treatment of
gastrointestinal symptoms, 223 portal hypertension, 521 -
gastroparesis, 273 Grymbowski, T. see Hotz, J.
gastropathy, 717 Guilford, S. A. see Morrison, G.
Gertner, D.J., Rampton, D.S., Stevens, T.R. J, Guillemot, F. see Cortot, A.
Lennard-Jones, J.E., Verapamil inhibits in-vitro
leucotriene B4 release by rectal mucosa in active H* K*-ATPase inhibitors, 197
ulcerative colitis, 163 H,-antagonists, 381
Giaffer, M.H., Holdsworth, C. D., Lennard-Jones, H,-receptor antagonists, 597
J. E., Rodrigues, C. A., McIntyre, P. B., Manjunatha, H. pylori eradication, 427
S., Baron, J. H., Barrison, I. G., Polson, R. J., Hoare, haemodynamics, 521
A. M., Davies, G. S. R., Thornton, P. C., Improved Hage, E. see Hendel, L.
maintenance of remission in ulcerative colitis by Haines, D.J., Bibbey, D., Green, J. R. B., The effects of
balsalazide 4 g/day compared with 2 g/day, 479 flumazenil on alertness and hypoxia in elderly
Giaffer, M.H., O’Brien, C. J., Holdsworth, C. D., patients after ERCP, 745
Clinical tolerance to three 5-aminosalicylic acid Halter, F. see Schuerer-Maly, C.-C.
releasing preparations in patients with inflamma- Hannan, A., Weil, J., Broom, C., Walt, R. P., Effects of
tory bowel disease intolerant or allergic to sul- oral pantoprazole on 24-hour intragastric acidity
phasalazine, 51 and plasma gastrin profiles, 373
Gibson, J. A. see Green, J. R. B. Harrison, G. see Bell, G. D.
Gibson, R. see Kendall, M. J. Hawkey, C. J. see Cole, A. T.
Gilmore, I. T. see Grimmer, S. F. M. Hawthorne, A. B. see Cole, A. T.
Glaxo Erosive Esophagitis Study Group see Roufail, Hayes, P. C. see Grose, R. D.
W. heartburn relief, 597
Go, M. F. see Graham, D. Y. Heatley, R. V., Review article: the treatment of
Goldschmiedt, M. see Feldman, M. Helicobacter pylori infection, 291
Graham, D. Y., see Malaty, H. Helicobacter pylori, 97, 113, 119, 171, 253, 291, 327,
Graham, D. Y., Correspondence, 653 389, 659, 757
Graham, D. Y., Go, M.F., Evans Jr, D.J., Review Helicobacter pylori therapy, 503
article: urease, gastric ammonium/ammonia, and Hendel, J. see Hendel, L.
Helicobacter pylori: the past, the present, and Hendel, L., Hage, E., Hendel, J., Stentoft, P., Ome-
recommendations for future research, 659 prazole in the long-term treatment of severe gastro-
granisetron, 273 oesophageal reflux disease in patients with syst-
Greaves, J. L. see Washington, N. emic sclerosis, 565
Green, J. R. B. see Haines, D. J. Hennig, U. see Hotz, J.
Green, J. R. B., Swan, C. H. J., Rowlinson, A., Gibson, Henry, M. M. see Jameson, J. S.
J. A., Brown, P., Kerr, G. D., Swarbrick, E. T., hepatotoxicity, 209
Thornton, P., Short report: comparison of two high performance liquid chromatography, 209
doses of balsalazide in maintaining ulcerative histamine, 335
colitis in remission over 12 months, 647 Hoare, A. M. see Giaffer, M. H.
Greenfield, S.M., Boswell, D.J., Punchard, N. A., Holcombe, C., Thom, C., Kaluba, J., Lucas, S. B.,
Thompson, R. P. H., The effects of 5-aminosalicylic Helicobacter pylori clearance in the treatment of non-
acid and acetyl-5-aminosalicylic acid on lipid ulcer dyspepsia, 119
peroxidation in erythrocytes and prostaglandin Holdsworth, C. D. see Giaffer, M. H.
production by mononuclear cells, 671 Hotz, J., Kleinert, R., Grymbowski, T., Hennig, U.,
Greski, P. A. see Sanders, S. W. Schwarz, J. A., Lansoprazole versus famotidine:
Grimmer, S. F. M., Back, D. J., L'E Orme, M., Tjia, efficacy and tolerance in the acute management of
J. F., Gilmore, I. T., Ellis, A., The in-vitro mucosal duodenal ulceration, 87
conjuction of ethinyloestradiol and the bioavaila- Houghton, L. A., Fowler, P., Keene, O.N., Read,
bility of oral contraceptive steroids in patients with N. W., Effect of sumatriptan, a new selective 5HT,-
treated and untreated coeliac disease, 79 like agonist, on liquid gastric emptying in man, 685
Grose, R. D., Hayes, P. C., Review article: the patho- Howden, C. W. see Chiverton, S. G.
INDEX 767
Hoyos, P. A. see Sanders, S. W. methacin: effects on pharmacokinetics, abdominal
Hudson, M. see Fraser, A. G. symptoms and bowel habit, 437
Hudson, N. see Cole, A. T. Kerr, G. D. see Green, J. R. B.
human gastrointestinal transit, 415 Khan, F. see Swift, G. L.
human jejunum, 619 Kim, M. see Riley, S. A.
Hunt, R. H. see Chiverton, S. G. Klein, P. D. see Malaty, H.
Hunt, J. B., Thillainayagam, A. V., Carnaby, S., Fair- Kleinert, R. see Hotz, J.
clough, P. D., Clark, M.L., Farthing, M.J.G., A Koop, H., Review article: metabolic consequences of
new model of human secretory diarrhoea using long-term inhibition of acid secretion by ome-
cholera toxin, 619 prazole, 399
hydrochlorothiazide, 701 Korman, M. see Pounder, R. E.
hydrocortisone, 357 Kristensen, A. see Brenna, E.
hyperbilirubaemia, 209 Kromer, W. see Schuerer-Maly, C.-C.
hypergastrinaemia, 197, 335
lazigi, N. see Figueiredo, M. C. A. lactase deficiency, 61
Iftikhar, S. Y. see Washington, N. lactase malabsorption, 61
lishi, H. see Tatsuta, M. Lam, W. M. see Prewett, E. J.
indomethacin, 453, 717 Langholz, E., Brynskov, J., Bendtzen, K., Vilien, M.,
inflammatory bowel disease, 51, 165 Binder, V., Treatment of Crohn’s disease with
interleukin-1, 495 fusidic acid: an antibiotic with immunosuppressive
interleukin-2, 495 properties similar to cyclosporin, 495
intestinal perfusion, 619 lansoprazole, 87
intestinal secretion, 619 Lastovica, A. see Young, G. P.
intragastric acidity, 103 L'E Orme, M. see Grimmer, S. F. M.
irritable bowel syndrome, 273 Lecomte, J. M. see Bergmann, J. F.
isosorbide dinitrate, 507 Lennard-Jones, J. E. see Gertner, D. J.
Lennard-Jones, J. E. see Giaffer, M. H.
Jameson, J. S., Kapadia, S. A., Polson, R. J., McCarthy, leucotrienes, 165
P. T., Misiewicz, J. J., ls oropharyngeal anaesthesia Levi, S. see Moss, S. F.
with topical lignocaine useful in upper gastrointes- lignocaine, 739
tinal endoscopy?, 739 lipid peroxidation, 671
Jameson, J. S., Rogers, J., Misiewicz, J. J., Raimundo, lipoxygenase, 165
A.H., Henry, M.M., Oral or intravenous ery- liquid emptying, 685
thromycin has no effect on human distal colonic Londong, W., Phillips, J., Johnson, N. J., Wood, J. R.,
motility, 589 The effect of combined therapy with ranitidine and
Jennings, D. E. see Sanders, S. W. pirenzepine in the treatment of reflux oesophagitis,
Johnson, N. J. see Londong, W. 609
Jones, P. H. see Bell, G. D. Louchahi, K. see Petitjean, O.
Louw, J. A. see Young, G. P.
Kaluba, J. see Holcombe, C. loxitidine, 335
Kammereit, A. see Madaus, S. Lucas, S. B. see Holcombe, C.
Kapadia, S. A. see Jameson, J. S. Luk, Y. W. see Prewett, E. J.
Keane, C. see Patchett, S.
Keene, O. N. see Houghton, L. A. McCarthy, P. T. see Jameson, J. S.
Kemmer, T. P., Malfertheiner, P., Buchler, M., Friess, McColl, K. E. see Fullarton, G. M.
H., Meschenmoser, L., Ditschuneit, H., Inhibition McCracken, K. H. see Morrison, G.
of human exocrine pancreatic secretion by the McIntyre, A. S., Thompson, D. G., Burnham, W. R.,
long-acting somatostatin analogue octreotide Walker, E., The effect of alpha-1-adrenoreceptor
(SMS 209-995), 41 agonist and antagonist administration on human
Kendall, M. J., Gibson, R., Walt, R. P., Co-adminis- upper gastrointestinal transit and motility, 415
tration of misoprostol or ranitidine with indo- McIntyre, A. S., Thompson, D. G., Review article:
768 INDEX
adrenergic control of motor and secretory function affecting gastrin, H. pylori or gastritis in duodenal
in the gastrointestinal tract, 125 ulcer patients, 257
McIntyre, P. B. see Giaffer, M. H. motilin receptors, 589
Madaus, S., Schulte-Frohlinde, E., Scherer, C., Kam- motility, 273
mereit, A., Schusdziarra, V., Classen, M., Compari- mucosal injury, 707
son of plasma bismuth levels after oral dosing with multicentre trial, 609
basic bismuth carbonate or tripotassium dicitrato
bismuthate, 241 Nakaizumi, A. see Tatsuta, M.
magnesium salts, 447 Nicolas, P. see Petitjean, O.
Mahida, Y. R. see Cole, A. T. nifadipine, 507
maintenance therapy, 727 night-time dosing, 381
maintenance treatment, 315, 479 non-cardiac chest pain, 273
malabsorption, 399 non-ulcer dyspepsin, 119, 273, 291
Malaty, H., Klein, P. D., Graham, D. Y., Short report: NSAIDs, 67, 717
cefprozil for the eradication of Helicobacter pylori
infection, 503
O'Brien, C. J. see Giaffer, M. H.
Malfertheiner, P. see Kemmer, T. P.
octreotide, 41
Malikova-Sekera, E. see Vatier, J.
oesophageal emptying, 507
Manjunatha, S. see Giaffer, M. H.
oesophagitis, 565
Marks, I. N. see Young, G. P.
Okuda, S. see Tatsuta, M.
Matsuda, N. M. see Figueiredo, M. C. A.
Oliveira, R. B. see Figueiredo, M. C. A.
meal-stimulated, 189
Oliver, P. S. see Ford, G. A.
Melarange, R., Moore, G., Blower, P. R., Coates,
omeprazole, 103, 181, 335, 399, 469, 565
M. E., Ward, F. W., Ronaasen, V., A comparison of
omeprazole (+ amoxycillin), 751
indomethacin with ibuprofen on gastrointestinal
O’Mearain, C. see Patchett, S.
mucosal integrity in conventional and germ-free
ondansetron, 273
rats, 67
opiate receptors, 305
Meschenmoser, L. see Kemmer, T. P.
opioid peptides, 305
Mesolazine, 261
oropharyngeal anaesthesia, 739
methionine, 231
metronidazole, 113, 327, 427
metronidazole sensitivity, 751 Page, J. G. see Sanders, S. W.
metronidazole resistance, 427 Pallecaros, A. see Bell, G. D.
Mignon, M. see Vatier, J. Pancrease HL, 549
Miller, P. F. see Uden, S. pancreatic secretion, 41
Mills, C. M. see Swift, G. L. pancreatic supplement, 549
Misiewicz, J. J. see Jameson, J. S. pantaprazole, 373
misoprostol, 437 Pappo, M. see Cortot, A.
Modlin, I. M. see Young, G. P. parietal cell, 335
monochloramine, 659 Patchett, S., Beattie, S., Keane, C., O’Morain, C., Short
monoclonal radioimmunoassay, 459 report: short-term triple therapy for H. pylori-
Moore, G. see Melarange, R. associated duodenal ulcer disease, 113
Moore, J. G. see Sanders, S. W. Patel, N., Ward, U., Rogers, M.J., Primrose, J. N.,
Moreau, J. see Cortot, A. Night-time or morning dosing with H,-receptor
morning dosing, 381 antagonists: studies on acid inhibition in normal
Morrison, G., Morrison, J. M., Redmond, A. O.B., subjects, 381
Byers, C.A., McCracken, K.H., Dodge, J. A., pathogenesis, 659
Guilford, S. A., Comparison between a standard patient compliance, 181
pancreatic supplement and a high enzyme prepa- patients with reflux oesophagitis, 609
ration in cystic fibrosis, 549 Penston, J. G. see Boyd, E. J. S.
Morrison, J. M. see Morrison, G. Penston, J. G., Wormsley, K. G., Correspondence,
Moss, S. F., Thomas, D. M., Ayesu, K., Levi, S., Calam, 759 :
J., Sucralfate diminishes basal acid output without Penston, J.G., Wormsley, K.G., Nine years of
INDEX 769
maintenance treatment with ranitidine for patients portal hypertension, 521
with duodenal ulcer disease, 629 protein buffer, 447
Penston, J. P. Wormsley, K. G., Review article: main- proton pump, 291, 399
tenance treatment with H,-receptor antagonists for proton pump inhibitor, 87, 373
peptic ulcer disease, 3 Punchard, N. A. see Greenfield, S. M.
pepsinogen, 335 Purser, K. see Bell, G. D.
pepsinogen secretion, 171
peptic ulcer, 181, 291, 359
Quatrini, M. see Delle Fave, G.
Pepto-Bismol, 97
Perret, G. see Petitjean, O.
Peterson, W. L. see Pounder, R. E. radiopaque markers, 305
Petitjean, O., Wendling, J. L., Tod, M., Loughahi, K., Raimundo, A. H. see Jameson, J. S.
Nicolas, P., Perret, G., Astier, A., Pharmacokinetics Rampton, D. S. see Gertner, D. J.
and absolute rectal bioavailability of hydrocorti- randomised double-blind, 609
sone acetate in distal colitis, 351 ranitidine, 181, 269, 437, 487, 597, 693, 707
pharmacokinetics, 103, 357, 437, 459 ranitidine plus pirenzepine, 609
pharmacotherapy, 521 ranitidine plus pirenzepine placebo, 609
phenylephrine, 415 Read, N. W. see Houghton, L. A.
Phillips, J. see Londong, W. rectal administration, 351
plasma ethanol, 693 rectum, 165
plasma gastrin, 389 recurrent pancreatitis, 231
plasma pepsinogen II, 389 Redmond, A. O. B. see Morrison, G.
Polson, R. J. see Giaffer, M. H. reflux oesophagitis, 181
Polson, R. J. see Jameson, J. S. renzapride, 273
polyethylene glycol, 513 Rhodes, J. see Swift, G. L.
portal hypertension, 521 Riley, S.A., Kim, M., Sutcliffe, F., Rowland, M.,
post-prandial ethyl alcohol, 269 Turnberg, L. A., Absorption of polar drugs follow-
Postius, S. see Schuerer-Maly, C.-C. ing caecal instillation in healthy volunteers, 701
potassium, 407 Robinson, M. see Roufail, W.
Pounder, R. E. see Fraser, A. G. Rodgers, W. H. see Bluhm, R. E.
Pounder, R. E. see Prewett, E. J. Rodrigues, C. A. see Giaffer, M. H.
Pounder, R. E., Festen, H., Korman, M., The long-term Rogers, J. see Jameson, J. S.
management of duodenal ulceration using an H,- Rogers, M. J. see Patel, N.
antagonist: symptomatic self-care compared with Ronaasen, V. see Melarange, R.
maintenance treatment, 315 Rosalki, S. B. see Fraser, A. G.
Pounder, R.E., Peterson, W.L., A letter from the Roter tablets, 97
Editors, 1 Roufail, W., Belsito, A., Robinson, M., Barish, C.,
Powell, K. see Bell, G. D. Rubin, A., Glaxo Erosive Esophagitis Study Group,
Powell, K. see Weil, J. Ranitidine for erosive oesophagitis : a double-blind,
Powell, K. U. see Bell, G. D. placebo-controlled study, 597
prednisolone, 31 Rowland, M. see Riley, S. A.
Prewett, E. J. see Fraser, A. G. Rowlinson, A. see Green, J. R. B.
Prewett, E. J., Luk, Y. W., Fraser, A. G., Lam, W. M., Rubin, A. see Roufail, W.
Pounder, R. E., Comparison of one-day oral dosing
with three bismuth compounds for the suppression salicylic acid, 701
of Helicobacter pylori assessed by the “C-urea salicylosulfapyridine, 165
breath test, 97 Samloff, I. M. see Fraser, A. G.
primary biliary cirrhosis, 459 Sanders, S. W., Moore, J. G., Day, G. M., Tolman,
Primrose, J. N. see Patel, N. K.G., Circadian differences in pharmacological
propylthiouracil, 541 blockade of meal-stimulated gastric acid secretion,
Prosser, S. see Bell, G. D. 187
prostaglandin production, 671 Sanders, S. W., Tolman, K. G., Greski, P. A., Jennings,
prostaglandins, 165 D.E., Hoyos, P. A., Page, J.G., The effects of
770 INDEX
lansoprazole, a new H*, K*-APTase inhibitor, on agonists and antagonists in the modulation of
gastric pH and serum gastrin, 359 gastrointestinal motility and sensation — clinical
sandostatin, 41 implications, 273
Sandvik, A. K. see Brenna, E. Tatsuta, M., lishi, H., Nakaizumi, A., Okuda, S., Effect
Sawyerr, A. M. see Fraser, A. G. of treatment with cisapride alone or in combination
Schalm, S. W. see Beukers, R. with domperidone on gastric emptying and gas-
Scherer, C. see Madaus, S. trointestinal symptoms in dyspeptic patients, 221
Schofield, D. see Uden, S. Tavares, I. A. see Swift, G. L.
Schuerer-Maly, C.-C., Kromer, W., Flogerzi, B., Varga, tetracycline, 113
L., Postius, S., Halter, F., Effect of acute and chronic therapeutic drug monitoring, 209
acid suppression on plasma gastrin release in the Thillainayagam, A. V. see Hunt, J. B.
rat, 195 Thom, C. see Holcombe, C.
Schulte-Frohlinde, E. see Madaus, S. Thomas, D. M. see Moss, S. F.
Schulze Sognen, B. see Brenna, E. Thompson, D. G. see Mcintyre, A. S.
Schusdziarra, V. see Madaus, S. Thompson, R. P. H. see Greenfield, S. M.
Schwartz, J. C. see Bergmann, J. F Thornton, P. C. see Giaffer, M. H.
Schwarz, J. A. see Hotz, J. Thornton, P. see Green, J. R. B.
scleroderma, 565 thymoxamine, 415
selenium, 231 time factors, 487
serotonin, 273 Tjia, J. F. see Grimmer, S. F. M.
Shepherd, N. A. see Ford, G. A. Tod, M. see Petitjean, O.
short-term treatment, 87 tolerance, 51
side-effects, 495 tolerance of endoscopy, 739
Smith, M. see Fraser, A. G. Tolman, K. G. see Sanders, S. W.
SMS 201-995, 41 Torsoli, A. see Delle Fave, G.
sodium picosulphate, 513 transplant, 209
somatostatin, 41 treatment, 113, 119
Sorge, M. see Corazza, G. R. tripotassium dicitrato bismuthate, 97, 113, 327, 751
Soule, J. C. see Cortot, A. tripotassium dicitrato bismuthate in tetracyline, 427
Spencer, G. see Bell, G. D. trophic effect, 335
Stemment, N. see Young, G. P. Trowell, J. E. see Bell, G. D.
Stentoft, P. see Hendel, L. Turnberg, L. A. see Riley, S. A.
Stevens, T. R. J. see Gertner, D. J.
Strocchi, A. see Corazza, G. R.
Uden, S., Schofield, D., Miller, P.F., Day, J. P.,
sulcralfate, 253
Bottiglier, T., Braganza, J. M., Antioxidant therapy
sulphasalazine, 51, 261
for recurrent pancreatitis: biochemical profiles in a
sulphasalazine test, 305
placebo-controlled trial, 229
Sutcliffe, F. see Riley, S. A.
ulcer relapse, 87
Swan, C. H. J. see Green, J. R. B.
ulcerative colitis, 31, 165, 479, 647
Swarbrick, E. T. see Green, J. R. B.
ulcers, 707
Swift, G. L., Arnold, J., Williams, G. T., Williams,
urea, 659
B. D., Rhodes, J., Khan, F., A comparison of upper
urea breath test, 503
gastrointestinal mucosal damage by standard and
urease, 659
delayed-release indomethacin, 717
Swift, G. L., Mills, C. M., Rhodes, J., Evans, B. K.,
Bennett, A., Tavares, I. A., A pharmacokinetic Van Den Berg, J. W. O. see Beukers, R.
study of sulphasalazine and two new formulations Van Den Merwe, E. L. see Young, G. P.
of mesalazine, 259 Varga, L. see Schuerer-Maly, C.-C.
sympathetic nerves, 125, 253 Vatier, J., Malikova-Sekera, E., Vitre, M. T., Mignon,
symptom relief, 609 M., An artificial stomach—duodenum model for the
symptomatic self-care, 315 in-vitro evaluation of antacids, 447
verapamil, 165
Talley, N.J., Review article: 5-hydroxytryptamine Veyrac, M. see Cortot, A.
INDEX 771
Vilien, M. see Langholz, E. Weil, J. see Hannan, A.
vitamin B,,, 399 Weil, J. Bell, G. D., Powell, K., Correspondence, 395
vitamin C, 231 Wendling, J. L. see Petitjean, O.
vitamin E, 231 Wilkinson, G. R. see Bluhm, R. E.
Vitre, M. T. see Vatier, J. Wilkinson, S. P. see Ford, G. A.
Williams, B. D. see Swift, G. L.
Waldum, H. L. see Brenna, E. Williams, G. T. see Swift, G. L.
Walker, E. see McIntyre, A. S. Wood, J. R. see Londong, W.
Walt, R. P. see Hannan, A. Wormsley, K. G. see Boyd, E. J. S.
Walt, R. P. see Kendall, M. J. Wormsley, K. G. see Penston, J. G.
Ward, F. W. see Melarange, R. Wormsley, K. G. see Penston, J. P.
Ward, U. see Patel, N.
Washington, N., Greaves, J.L., Iftikhar, S. Y. A Young, G. P., Stemment, N., Lastovica, A., Van Den
comparison of gastro-oesophageal reflux in volun- Merwe, E. L., Louw, J. A., Modlin, I. M., Marks,
teers assessed by ambulatory pH and gamma I. N., Helicobacter pylori lipopolysaccharide stimu-
monitoring after treatment with either Liquid lates gastric mucosal pepsinogen secretion, 169
Gaviscon or Algicon Suspension, 579
Weil, J. see Bell, G. D. zacopride, 273